Galapagos NV (EURONEXT:GLPG)

European company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - GLPG

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - GLPG

  • Market Cap€7.305bn
  • SymbolEURONEXT:GLPG
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINBE0003818359

Company Profile

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.

Latest GLPG news

Currently there for this company. Visit our news hub for other news .